COVID-19: todo lo que necesitas saber
Afecciones destacadas Tumor cerebral, cáncer de mama, cáncer de colon, enfermedad cardíaca congénita, arritmia cardíaca. Para ver más afecciones.
Afecciones destacadas
A continuación se enumeran ensayos clínicos actuales.
Filtrar esta lista de estudios según la ubicación, el estado del estudio y más.
Rochester, Minn.
Jacksonville, Fla., Rochester, Minn.
Regorafenib might or might not slow down the growth of your tumor, or shrink your tumor. Regorafenib is approved in the United States to treat colon cancer and one form of sarcoma (GIST), but we do not know if regorafenib is useful to treat people with liposarcoma, osteosarcoma, and Ewing / Ewing-like sarcomas. One drug like regorafenib, called pazopanib, is approved to treat some sarcomas, but is not approved to treat liposarcoma, osteosarcoma. Since we do not know if any of these types of drugs help people with liposarcoma, osteosarcoma, or Ewing/Ewing-like sarcoma, our goal in this study is to find out if regorafenib is useful for people with your type of sarcoma.
The purpose of this study is to assess how well glembatumumab vedotin works in treating patients with osteosarcoma that has come back (recurrent) or does not respond to treatment (refractory). Monoclonal antibodies, such as glembatumumab vedotin, may find tumor cells and help kill them.